172 related articles for article (PubMed ID: 35546143)
21. Novel TOPK inhibitor HI-TOPK-032 effectively suppresses colon cancer growth.
Kim DJ; Li Y; Reddy K; Lee MH; Kim MO; Cho YY; Lee SY; Kim JE; Bode AM; Dong Z
Cancer Res; 2012 Jun; 72(12):3060-8. PubMed ID: 22523035
[TBL] [Abstract][Full Text] [Related]
22. The Protective Role of the TOPK/PBK Pathway in Myocardial Ischemia/Reperfusion and H₂O₂-Induced Injury in H9C2 Cardiomyocytes.
Sun G; Ye N; Dai D; Chen Y; Li C; Sun Y
Int J Mol Sci; 2016 Feb; 17(3):267. PubMed ID: 26907268
[TBL] [Abstract][Full Text] [Related]
23. Aberrant expression of PDZ-binding kinase/T-LAK cell-originated protein kinase modulates the invasive ability of human pancreatic cancer cells via the stabilization of oncoprotein c-MYC.
Hinzman CP; Aljehane L; Brown-Clay JD; Kallakury B; Sonahara F; Goel A; Trevino J; Banerjee PP
Carcinogenesis; 2018 Dec; 39(12):1548-1559. PubMed ID: 30165468
[TBL] [Abstract][Full Text] [Related]
24. Long non-coding RNA GAS5 sensitizes renal cell carcinoma to sorafenib via miR-21/SOX5 pathway.
Liu L; Pang X; Shang W; Xie H; Feng Y; Feng G
Cell Cycle; 2019 Feb; 18(3):257-263. PubMed ID: 29895198
[TBL] [Abstract][Full Text] [Related]
25. MiRNA-30a-mediated autophagy inhibition sensitizes renal cell carcinoma cells to sorafenib.
Zheng B; Zhu H; Gu D; Pan X; Qian L; Xue B; Yang D; Zhou J; Shan Y
Biochem Biophys Res Commun; 2015 Apr; 459(2):234-239. PubMed ID: 25712526
[TBL] [Abstract][Full Text] [Related]
26. TOPK promotes the growth of esophageal cancer in vitro and in vivo by enhancing YB1/eEF1A1 signal pathway.
Wu W; Xu J; Gao D; Xie Z; Chen W; Li W; Yuan Q; Duan L; Zhang Y; Yang X; Chen Y; Dong Z; Liu K; Jiang Y
Cell Death Dis; 2023 Jun; 14(6):364. PubMed ID: 37328464
[TBL] [Abstract][Full Text] [Related]
27. PBK/TOPK expression in non-small-cell lung cancer: its correlation and prognostic significance with Ki67 and p53 expression.
Lei B; Liu S; Qi W; Zhao Y; Li Y; Lin N; Xu X; Zhi C; Mei J; Yan Z; Wan L; Shen H
Histopathology; 2013 Nov; 63(5):696-703. PubMed ID: 24025073
[TBL] [Abstract][Full Text] [Related]
28. New frontiers against sorafenib resistance in renal cell carcinoma: From molecular mechanisms to predictive biomarkers.
He Y; Luo Y; Huang L; Zhang D; Wang X; Ji J; Liang S
Pharmacol Res; 2021 Aug; 170():105732. PubMed ID: 34139345
[TBL] [Abstract][Full Text] [Related]
29. Expression of PBK/TOPK in cervical cancer and cervical intraepithelial neoplasia.
Luo Q; Lei B; Liu S; Chen Y; Sheng W; Lin P; Li W; Zhu H; Shen H
Int J Clin Exp Pathol; 2014; 7(11):8059-64. PubMed ID: 25550851
[TBL] [Abstract][Full Text] [Related]
30. TOPK/PBK promotes cell migration via modulation of the PI3K/PTEN/AKT pathway and is associated with poor prognosis in lung cancer.
Shih MC; Chen JY; Wu YC; Jan YH; Yang BM; Lu PJ; Cheng HC; Huang MS; Yang CJ; Hsiao M; Lai JM
Oncogene; 2012 May; 31(19):2389-400. PubMed ID: 21996732
[TBL] [Abstract][Full Text] [Related]
31. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
Radulovic S; Bjelogrlic SK
J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
[TBL] [Abstract][Full Text] [Related]
32. Autophagic cell death associated to Sorafenib in renal cell carcinoma is mediated through Akt inhibition in an ERK1/2 independent fashion.
Serrano-Oviedo L; Ortega-Muelas M; García-Cano J; Valero ML; Cimas FJ; Pascual-Serra R; Fernandez-Aroca DM; Roche O; Ruiz-Hidalgo MJ; Belandia B; Giménez-Bachs JM; Salinas AS; Sanchez-Prieto R
PLoS One; 2018; 13(7):e0200878. PubMed ID: 30048489
[TBL] [Abstract][Full Text] [Related]
33. Phosphorylation of IκBα at serine 32 by T-lymphokine-activated killer cell-originated protein kinase is essential for chemoresistance against doxorubicin in cervical cancer cells.
Park JH; Yoon DS; Choi HJ; Hahm DH; Oh SM
J Biol Chem; 2013 Feb; 288(5):3585-93. PubMed ID: 23250755
[TBL] [Abstract][Full Text] [Related]
34. MicroRNA-216b-3p inhibits lung adenocarcinoma cell growth via regulating PDZ binding kinase/T-LAK-cell-originated protein kinase.
Chai Y; Xue H; Wu Y; Du X; Zhang Z; Zhang Y; Zhang L; Zhang S; Zhang Z; Xue Z
Exp Ther Med; 2018 Jun; 15(6):4822-4828. PubMed ID: 29805502
[TBL] [Abstract][Full Text] [Related]
35. TOPK mediates immune evasion of renal cell carcinoma via upregulating the expression of PD-L1.
Li J; Sun H; Fu M; Zheng Z; Xu C; Yang K; Liu Y; Xuan Z; Bai Y; Zheng J; Zhao Y; Shi Z; Shao C
iScience; 2023 Jul; 26(7):107185. PubMed ID: 37404377
[TBL] [Abstract][Full Text] [Related]
36. PBK/TOPK Inhibitor Suppresses the Progression of Prolactinomas.
Zhu K; Cheng X; Wang S; Zhang H; Zhang Y; Wang X; Chen Y; Wu J
Front Endocrinol (Lausanne); 2021; 12():706909. PubMed ID: 35126305
[TBL] [Abstract][Full Text] [Related]
37. Antitumor effects of a combination of interferon-alpha and sorafenib on human renal carcinoma cell lines.
Tochizawa S; Masumori N; Yanai Y; Ohmoto Y; Yabuuchi Y; Tsukamoto T
Biomed Res; 2008 Dec; 29(6):271-8. PubMed ID: 19129670
[TBL] [Abstract][Full Text] [Related]
38. Novel selective TOPK inhibitor SKLB-C05 inhibits colorectal carcinoma growth and metastasis.
Gao T; Hu Q; Hu X; Lei Q; Feng Z; Yu X; Peng C; Song X; He H; Xu Y; Zuo W; Zeng J; Liu Z; Yu L
Cancer Lett; 2019 Mar; 445():11-23. PubMed ID: 30590102
[TBL] [Abstract][Full Text] [Related]
39. T-lymphokine-activated killer cell-originated protein kinase functions as a positive regulator of c-Jun-NH2-kinase 1 signaling and H-Ras-induced cell transformation.
Oh SM; Zhu F; Cho YY; Lee KW; Kang BS; Kim HG; Zykova T; Bode AM; Dong Z
Cancer Res; 2007 Jun; 67(11):5186-94. PubMed ID: 17545598
[TBL] [Abstract][Full Text] [Related]
40. The T-LAK Cell-originated Protein Kinase Signal Pathway Promotes Colorectal Cancer Metastasis.
Zykova TA; Zhu F; Wang L; Li H; Bai R; Lim DY; Yao K; Bode AM; Dong Z
EBioMedicine; 2017 Apr; 18():73-82. PubMed ID: 28412249
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
